The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 08, 2014

Filed:

Oct. 11, 2012
Applicants:

Merck Frosst Canada Inc., Kirkland, Quebec, CA;

Axys Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Christopher I. Bayly, Santa Fe, NM (US);

Cameron Black, Baie d'Urfe, CA;

Serge Leger, Notre-Dame-de I'lle-Perrot, CA;

Chun Sing Li, Dollard-des-Ormeaux, CA;

Dan McKay, Ottawa, CA;

Christophe Mellon, Saint-Redempteur, CA;

Jacques Yves Gauthier, Montreal, CA;

Vouy-Linh Truong, Quebec, CA;

Cheuk Lau, L'lle Bizard, CA;

Michel Therien, Laval, CA;

Michael J. Green, Half Moon Bay, CA (US);

Bernard L. Hirschbein, San Francisco, CA (US);

James William Janc, Burlingame, CA (US);

James T. Palmer, Corte Madera, CA (US);

Chitra I. Baskaran, Foster City, CA (US);

Assignees:

Merck Frosst Canada Ltd., Kirkland, Quebec, CA;

Axys Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/275 (2006.01); A61K 31/69 (2006.01); A61K 31/4965 (2006.01); A61K 31/44 (2006.01); A61K 31/425 (2006.01); A61K 31/415 (2006.01); A61K 31/535 (2006.01); A61K 31/38 (2006.01); A61K 31/42 (2006.01); A61K 31/405 (2006.01); A61K 31/47 (2006.01); C07D 401/04 (2006.01);
U.S. Cl.
CPC ...
Abstract

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.


Find Patent Forward Citations

Loading…